ZA200901981B - Novel diphenylazetidinone substituted by piperazine-1-sulfonic acid having improved pharmacological properties - Google Patents

Novel diphenylazetidinone substituted by piperazine-1-sulfonic acid having improved pharmacological properties

Info

Publication number
ZA200901981B
ZA200901981B ZA200901981A ZA200901981A ZA200901981B ZA 200901981 B ZA200901981 B ZA 200901981B ZA 200901981 A ZA200901981 A ZA 200901981A ZA 200901981 A ZA200901981 A ZA 200901981A ZA 200901981 B ZA200901981 B ZA 200901981B
Authority
ZA
South Africa
Prior art keywords
diphenylazetidinone
piperazine
substituted
novel
sulfonic acid
Prior art date
Application number
ZA200901981A
Other languages
English (en)
Inventor
Gerhard Jaehne
Wendelin Frick
Andreas Lindenschmidt
Hubert Heuer
Hans-Ludwig Schaefer
Werner Kramer
Claus-Dieter Graf
Wolfgang Schmider
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of ZA200901981B publication Critical patent/ZA200901981B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA200901981A 2006-11-02 2009-03-20 Novel diphenylazetidinone substituted by piperazine-1-sulfonic acid having improved pharmacological properties ZA200901981B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006051655 2006-11-02

Publications (1)

Publication Number Publication Date
ZA200901981B true ZA200901981B (en) 2010-03-31

Family

ID=38875004

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200901981A ZA200901981B (en) 2006-11-02 2009-03-20 Novel diphenylazetidinone substituted by piperazine-1-sulfonic acid having improved pharmacological properties

Country Status (20)

Country Link
US (1) US20090264402A1 (zh)
EP (1) EP2091915A1 (zh)
JP (1) JP2010508313A (zh)
KR (1) KR20090091120A (zh)
CN (1) CN101535249A (zh)
AR (1) AR063747A1 (zh)
AU (1) AU2007315327A1 (zh)
BR (1) BRPI0718052A2 (zh)
CA (1) CA2668094A1 (zh)
CL (1) CL2007003175A1 (zh)
CO (1) CO6160306A2 (zh)
IL (1) IL198427A0 (zh)
MA (1) MA30819B1 (zh)
MX (1) MX2009003823A (zh)
NO (1) NO20091746L (zh)
RU (1) RU2009120679A (zh)
TW (1) TW200826941A (zh)
UY (1) UY30682A1 (zh)
WO (1) WO2008052658A1 (zh)
ZA (1) ZA200901981B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20100286112A1 (en) 2007-09-10 2010-11-11 Oscar Barba Compounds for the treatment of metabolic disorders
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
BR112013004882A2 (pt) 2010-08-31 2016-05-03 Snu R&Db Foundation utilização de reprogramação fetal de agonista ppar delta
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ME03564B (me) 2013-03-13 2020-07-20 Forma Therapeutics Inc DERIVATI 2-HIDROKSI-1-{4-[(4-FENILFENIL)KARBONIL]PIPERAZIN-1-IL}ETAN-1-ONA l SRODNA JEDINJENJA KAO INHIBITORI SINTAZE MASNIH KISELINA (FASN) ZA LEČENJE KANCERA
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
CN104513187B (zh) * 2015-01-09 2017-05-31 安润医药科技（苏州）有限公司 依折麦布及其中间体的合成方法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10227506A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders

Also Published As

Publication number Publication date
CO6160306A2 (es) 2010-05-20
WO2008052658A1 (de) 2008-05-08
NO20091746L (no) 2009-07-21
EP2091915A1 (de) 2009-08-26
CN101535249A (zh) 2009-09-16
AR063747A1 (es) 2009-02-18
US20090264402A1 (en) 2009-10-22
TW200826941A (en) 2008-07-01
MA30819B1 (fr) 2009-10-01
UY30682A1 (es) 2008-07-03
CA2668094A1 (en) 2008-05-08
AU2007315327A1 (en) 2008-05-08
KR20090091120A (ko) 2009-08-26
CL2007003175A1 (es) 2008-05-16
RU2009120679A (ru) 2010-12-10
BRPI0718052A2 (pt) 2015-06-16
JP2010508313A (ja) 2010-03-18
IL198427A0 (en) 2010-02-17
MX2009003823A (es) 2009-05-11

Similar Documents

Publication Publication Date Title
ZA200901981B (en) Novel diphenylazetidinone substituted by piperazine-1-sulfonic acid having improved pharmacological properties
HK1136593A1 (en) Polylactic acid composition
EP1953191A4 (en) polylactic acid
ZA201103542B (en) Novel composition based on gamma-hydroxybutric acid
GB0619060D0 (en) Novel process
EP2034838A4 (en) NOVEL CONNECTIONS
HK1131402A1 (en) Polylactic acid composition
EP2032142A4 (en) NOVEL CONNECTIONS
EP1956045A4 (en) polylactic acid
EP1981596A4 (en) NEW CONNECTIONS
GB0603550D0 (en) Novel compounds
EP1981900A4 (en) NEW COMPOUNDS
GB0605462D0 (en) Novel compounds
SI1981972T1 (sl) Nov postopek
EP2072498A4 (en) N-PHENYLOXAMIDE ACID DERIVATIVE
GB0625275D0 (en) Novel process
HK1151801A1 (en) 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid
GB0617366D0 (en) Novel process
GB0617367D0 (en) Novel process
EP2128136A4 (en) DERIVATIVE OF 2-PHENYLNICOTINIC ACID
TWM298391U (en) Improved structure of bar
GB0624660D0 (en) Novel process
GB0625043D0 (en) Novel compound
IL176314A0 (en) Electrity production by wind
GB0611931D0 (en) Novel insulation biomaterials